key: cord-0718757-p8z3os9r
authors: Steens, A.; Knol, M. J.; Freudenburg-de Graaf, W.; de Melker, H. E.; van der Ende, A.; van Sorge, N. M.
title: Pathogen- and type-specific changes in invasive bacterial disease epidemiology during the first year of the COVID-19 pandemic in the Netherlands
date: 2022-04-19
journal: nan
DOI: 10.1101/2022.04.19.22273034
sha: ee7f5e4dc73a977c4c91070434ac80c4c3121519
doc_id: 718757
cord_uid: p8z3os9r

The COVID-19 control measures have resulted in a decline in several invasive bacterial disease caused by Neisseria meningitidis (IMD), Streptococcus pneumoniae (IPD) and Haemophilus influenzae (Hi-D). Since these species comprise different serogroups and serotypes that impact transmissibility and virulence, we evaluated type- and pathogen-specific changes in invasive bacterial disease epidemiology in the Netherlands during the first year of the SARS-CoV-2 pandemic. Cases were based on nationwide surveillance for five bacterial species with either respiratory (IMD, IPD, Hi-D) or non-respiratory (controls) transmission routes. Cases and type-distribution were compared between the pre-COVID period (2015-March 2020) and the first COVID-19 year (April 2020-March 2021). Overall, IMD, IPD, and Hi-D cases decreased by 78%, 67%, and 35%, respectively, in the first COVID-19 year compared to the pre-COVID period although effects differed per age group. Invasive bacterial disease in infants caused by Streptococcus agalactiae and Escherichia coli did not decrease, suggesting stable isolate submission. Serogroup B-IMD declined by 61%, while serogroup W and Y-IMD decreased >90%. Changes in IPD were dependent on pneumococcal serotypes, with 7F, 15A, 12F, 33F, and 8 showing the most pronounced decline ([≥]76%). In contrast to an overall decrease in Hi-D cases, vaccine-preventable serotype b (Hib) increased by 51%. In summary, the implementation of COVID-19 control measures had pathogen- and type-specific effects related to bacterial infections, likely reflecting intrinsic differences in transmissibility and age-related differences in (adherence to) control measures. Continued surveillance is critical to monitor potential rebound effects once restriction measures are lifted and transmission is resumed.

Invasive bacterial infections, such as meningitis and sepsis, are associated with high rates of mortality and morbidity worldwide. In the Netherlands as well as globally, the most common causes of bacterial invasive disease differ per age group and availability and implementation of preventive measures 1 [1] [2] [3] [4] , decreasing the incidence of invasive bacterial disease caused by vaccine-covered serotype-and serogroup-specific pathogens in children by > 90% 1, 7, 8 . Additionally, declines of these targeted serogroups and -types have been observed in non-targeted age groups as a result of indirect protection 2, 9 .

The occurrence of the COVID-19 pandemic in 2020 resulted in the implementation of public health response measures such as working from home, social 1.5-meter distancing, and school and day care closures, which varied in stringency and enforcement, from March 15, 2020 onwards 10 . These control measures did not just limit transmission and subsequent disease caused by SARS-CoV-2, but concomitantly interrupted person-to-person transmission of other pathogens. Indeed, a decline in the incidence of invasive bacterial infections with respiratory transmission including those caused by N. meningitidis (IMD), S. pneumoniae (IPD) and H. influenzae (Hi-D) has been observed in many countries and regions [11] [12] [13] . In contrast, the incidence of neonatal invasive diseases caused by S. agalactiae appears to have been unaffected by the COVID-19-related measures 11 . Indeed, transmission of this pathogen is likely unaffected by control measures as transmission results from vertical instead of respiratory transmission. This is also the case for neonatal invasive disease caused by E. coli. Therefore, invasive disease cases due to these (neonatal) pathogens can be used as a control to exclude impact of the pandemic on isolate submission by microbiology laboratories.

Here, we retrospectively analysed changes in the epidemiology of invasive bacterial diseases in the Netherlands during the first year of the SARS-CoV-2 pandemic, with specific focus on differences between bacterial species and subtypes. We compared the number of cases and incidence of invasive 

Nationwide surveillance data were obtained from the Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM) for all studied pathogens. The NRLBM receives bacterial isolates from patients with invasive bacterial disease (isolated from blood and/or cerebrospinal fluid, CSF), including IPD for children < 5 years of age, and Hi-D and IMD isolates from patients of all ages. In addition, IPD isolates from patients of all ages are received from nine sentinel laboratories, covering about 25% of the Dutch population. E. coli and S. agalactiae isolates recovered from blood or cerebrospinal fluid (CSF) are . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 19, 2022. ;  https://doi.org/10.1101/2022.04.19.22273034 doi: medRxiv preprint received from patients < 1 years of age. All isolates are typed according to the methods described below.

Typing of bacterial isolates N. meningitidis serogroup was determined by Ouchterlony gel diffusion 14 . In case of a culture-negative PCR-positive sample, N. meningitidis serogroup was determined by real-time PCR using group-specific probes 15 . S. pneumoniae and H. influenzae isolates were serotyped by co-agglutination with specific antisera. For S. pneumoniae, additional subtyping was assessed by capsular swelling (Quellung reaction) using specific antisera (Serum Staten Institute, Denmark) 16 . E. coli isolates were tested for expression of K1 antigen by phage typing according to the manufacturer (SSI Diagnostica) and H-and O-types based on whole-genome sequences 17 . S. agalactiae isolates were grouped (Lancefield B) and serotyped through agglutination using specific antisera 18 . For neonatal/infant invasive disease caused by E. coli and S. agalactiae, data of infants younger than one year were used, since this is resulting from vertical transmission and/or non-respiratory transmission. For N. meningitidis, S. pneumoniae, and H. influenzae, patients were categorized into agegroups as appropriate for the epidemiology of the respective pathogens. Specifically, for IPD and Hi-D, age categories included the under-fives, 5-64 years, and older adults (65+). For IMD, the 5-19-year olds and 20-64-year olds were analysed separately in addition to the under-fives and 65+ age groups. For IPD, the age group 73-79 years was excluded from the analyses to avoid a possible bias from the introduction of the PPV23 vaccine in autumn 2020 for this cohort.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 19, 2022 (2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, 33F) , and non-vaccine serotypes (all remaining serotypes). Non-typeable isolates and isolates with missing serotype information were excluded from the serotype-specific analyses. Specifically, this applied for 0.7% missing or non-typeable serotypes for S. pneumoniae, 0.9% missing or ungroupable serogroups for N. meningitidis, 0.1% missing serotypes for H. influenzae.

Analyses were performed separately for the different pathogens and serotypes/serogroups. The percentage change was determined as 1-(the number of cases in the COVID-19 year / the average number of cases in the five preceding years)*100. The 5-year moving average per month for the pre-COVID period was based on the targeted month, one month before and one after the targeted month.

The incidence was determined by dividing the number of cases in the defined years (April-March) by the number of inhabitants for the same period (for a specific age group) / 100,000. Population statistics were obtained from Statistics Netherlands. The percentage change per serotype/serogroup was determined relative to the number of isolates with known serotype/serogroup. For IPD, results on serotype-specific changes are presented if the serotype had a yearly average of at least 10 cases in the five pre-COVID-19 years. Ranking was used to determine whether serotypes increased/decreased differentially over time.

In accordance with Dutch law, approval from a medical ethics committee was not deemed necessary since cases were not subject to any actions or rules of conduct. Data regarding cases were obtained by use of standard surveillance procedures, and pseudonymised data were used in the study. Informed consent was not obtained, as the collection of data complies with the exceptions for not asking informed consent as formulated in the Dutch Implementation Act General Data Protection Regulation.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022 

year Overall, IMD, IPD, and Hi-D decreased by 78% (n=36 versus 163), 67% (n=175 versus 531) and 35% (n=144 versus 221) compared to the average number of cases in the preceding five years 2015-2020 (pre-COVID), respectively. The decrease was immediately apparent in April 2020, which is the first month following lock-down (15 March 2020), for all three pathogens ( Figure 1A -C). IMD and IPD case numbers remained lower compared to non-COVID years all throughout the first COVID-19 year ( Figure   1A , B). In contrast, Hi-D case numbers were similar or higher compared to the 5-year moving average in August, October, and December 2020 ( Figure 1C ). Invasive disease cases caused by S. agalactiae and E. coli showed an increase in the 2015-2020 period, with similar or increased number of cases in the first COVID-19 year (n=131 versus 82 on average and n=80 versus 50 on average, respectively; Figure   1D , E).

We assessed whether the reduction in invasive disease cases was similar across different age groups despite small numbers. For IMD and IPD, the reduction in invasive disease cases was observed across the different age categories studied; IMD and IPD cases were 58% (n=8 versus 17) and 53% (n=13 versus 31 pre-COVID) lower for children under the age of five years, and 86% (n=6 versus 43) and 69% (n=89 versus 283) lower in the 65+ population compared to the pre-COVID average. In contrast, Hi-D cases increased by 13% (n=38 versus 34) in the under-fives but decreased by 18% (n=63 versus 77) in 5-64year olds and 61% in the 65+ age group (n=42 versus 109). These age-specific differences can be explained by serotype-specific effects, as presented below.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022 

Of the 851 N. meningitidis isolates received during the study period, 397 (47%) were serogroup B, 29 

Overall, 2,830 IPD cases were included in the study. In the five pre-COVID-19 years, an average of 531 IPD isolates per year were submitted by the sentinel laboratories, resulting in an overall incidence of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We also analysed changes in the number of IPD cases caused by individual pneumococcal serotypes (Table 1) . Only serotypes that changed by more than 10% compared to the average change of allserotype IPD (67%) are discussed. The proportional increase among PCV13extra serotypes was mainly attributable to serotype 19A, which was less affected (50% decrease) than the average IPD decline (67%; Table 1 ). For PPV23 serotypes, a larger than average decrease was observed for serotypes 8 (76% decrease), 12F (82%), and 33F (87%), as well as non-vaccine serotype 15A (86%; Table 1 ). Of the nonvaccine serotypes, serotype 6C showed the smallest reduction, decreasing by only 16% compared to the average proportion in the previous five years (Table 1) . Note, however, that the ranking of the most . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101/2022.04.19.22273034 doi: medRxiv preprint common serotypes remained stable, with serotypes 19A and 8 being the two most common serotypes for all analysed years and serotypes 3, 7F, 22F and 9N remaining in the top 3-6 rank. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022 19 . We have focused our analysis on Hib and NTHi, since they cover 90% of all Hi-D cases. Overall, compared to the five preceding years, the number of Hi-D cases decreased by 35% (144 versus 221 on average) in the first COVID year ( Figure 1C ). However, there was great disparity between Hib and NTHi cases. The number of Hib cases increased by 51% (65 versus 43 on average) ( Figure 4A ) 19 , resulting in an incidence of 0.37/100,000 in the first COVID-19 year compared to 0.21-0.29/100,000 in the previous 5-year period. This increase was most pronounced in the age group 5-64 years (97% increase; n=26), followed by children < 5 years of age (42%; n=25) and 65+ year-olds (29%; n=15). In contrast, compared to the pre-COVID period, NTHi cases declined by 57% (n=67 versus 154 on average) ( Figure 4B ), lowering the incidence from 0.73-1.01/100,000 to 0.38/100,000. During the first COVID-19 year, the number of NTHi cases was significantly lower than the 5-year moving average during all months except in August (Figure 4 B) , whereas Hib cases were higher than the 5-year moving average for nearly all months (Figure 4 A) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022 

In the present study, we evaluated the effect of the implementation of public health measures in response to the COVID-19 pandemic by analysing epidemiological changes in the occurrence of invasive disease caused by different bacterial pathogens. We observed a 35% to 78% reduction in the incidence of invasive disease caused by N. meningitidis, S. pneumoniae and H. influenzae. In contrast, no decrease but a slight increase in infant invasive disease cases caused by S. agalactiae and E. coli was observed in the COVID-19-year compared to the 2015-2020 pre-COVID period, which is consistent with the observed trend already over a longer period. This suggests that national surveillance, which relies on voluntary isolate submission from clinical diagnostics laboratories, was not generally disrupted.

However, we cannot fully exclude that surveillance was affected by care and mass diagnostics of COVID-19 patients or that specific age groups were differentially affected as we were not able to estimate possible age-specific changes in our control group. Because of the surveillance system itself, with subtyping being done by the reference laboratory after isolate submission, it is unlikely that potential effects on surveillance would differ between sub-types. 20 .

A decrease in occurrence of IMD during the COVID-19 pandemic has been observed by many countries 11, 13 . For the results presented here, it is important to note that the MenACWY vaccine has been implemented in the Netherlands in 2018 5 . Consequently, the decrease in IMD cases caused by serotypes W and Y are partially influenced by the protective effect from MenACWY vaccination 6 . The decrease in MenB cases by 62% therefore most accurately reflects the impact of COVID-19 on IMD, since IMD-B disease is not affected by a recent introduction of a vaccine.

Changes in IPD were different for different serotypes. Specifically, serotypes 8, 12F, 33F (all in PPV23 but not in PCV10) and 15A (non-vaccine type) decreased more than other serotypes. In Taiwan, a similarly large decrease in serotype 15A was observed 21 . Serotypes 8, 12F, and 15A have been increasing in Europe before the COVID-19 pandemic and are known to have a high invasive capacity [22] [23] [24] [25] [26] . Generally, these serotypes are dominant in younger individuals and those without medical underlying conditions 22 . Unfortunately, we lack information on underlying medical risk conditions in . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022. ;  https://doi.org/10.1101/2022.04.19.22273034 doi: medRxiv preprint the study cohort. In contrast to the abovementioned serotypes, serotypes 19A and 6C showed a smaller decrease among IPD cases. This is of interest since these serotypes have become more common in pre-COVID years in several countries that use PCV10 27 , likely as a result of serotype replacement 28 .

Whether the relatively limited decrease can be partly explained by an offset caused by serotype replacement after PCV10 introduction is yet unknown 29 .

Our serotype-specific observations differ from reports by some other countries. In Germany, the proportion of vaccine serotypes (PCV13, PCV15, PCV20) remained constant during the COVID-19 control measures, although 12F and 22F seemed to represent a smaller proportion in 2021 than in earlier years indicating a larger decrease during COVID-times and "other serotypes" comprised a larger proportion in 2021 30 . In Taiwan, they noticed a large decrease in 19A in contrast to our modest reduction in this serotype 21 . Finally, in Switzerland, no serotype-specific patterns were observed during the period with COVID-19 control measures, although serotype 23B increased more than other serotypes after easing the non-pharmaceutical interventions 29 . Serotype-specific changes may reflect age-specific (adherence to) non-pharmaceutical interventions. Furthermore, the serotype-specific changes may reflect differences in propensity of these serotypes to cause secondary infections following respiratory viral infections. Indeed, there were large decreases in overall viral infections during the COVID-19 period, while carriage patterns were reported not to be affected during the COVID-19 pandemic 31 .

For Hi-D, there was a discrepancy in the changes during the COVID-19 year, which were attributed to different behaviour of serotypes. NTHi disease cases decreased across all age groups, whereas Hib increased in under-fives and 5-64-year olds (specifically in 50-64-year olds), but decreased in the 65+ population. The Hib increase during the first COVID-19 year is striking as preventive measures against COVID-19 were in place and diseases caused by other respiratory-transmitted pathogens decreased.

Although not the focus of this study, the vaccine effectiveness against Hib disease did not seem to be different from previous years 19 . We are currently investigating the possible cause of this increase in Hib disease.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022 Overall, we showed that the changes in epidemiology during the first COVID-19 year differed between pathogens, subtypes and age groups, with the largest discrepancy seen for Hib and NTHi. Our study indicates that overall the disease burden of respiratory bacterial pathogens was decreased by the preventive measures against COVID-19, but it also shows that other factors affected the epidemiology simultaneously; for IMD, the recent MenACWY-vaccination campaign likely played a role in the observed differences between serogroup B versus serogroup W and Y IMD. For Hib, unknown factors seem to have affected the epidemiology 19 . The differences in pneumococcal serotype-specific changes might be associated with the epidemic potential, invasive capacity, and/or propensity of the different serotypes to cause secondary infections. Possible differences by risk-group and age in (adherence to) control measures may have played a role in causing different decreases for different age groups.

Altogether, we stress the importance of subtype-specific surveillance, also during the COVID-19 pandemic and specifically when measures are relaxed again, given the worry that the interruption of transmission has created a larger group of susceptible individuals 32 .

This research received no external funding and is funded by the regular budget of the NRLBM and the Center for Infectious Disease Control of the RIVM.

NvS and AvdE were involved in data acquisition. All authors were involved in data analysis and interpretation. NvS prepared the original draft of the manuscript, which was reviewed and edited by all authors. All authors have approved the submitted version of the manuscript.

The data presented in the study are available on request with the corresponding author but are not publicly available due to regulations in the Personal Data Protection Act.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 19, 2022 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 19, 2022 

Changing Epidemiology of Bacterial Meningitis Since Introduction of Conjugate Vaccines: 3 Decades of National Meningitis Surveillance in The Netherlands

Twelve years of pneumococcal conjugate vaccination in the Netherlands: Impact on incidence and clinical outcomes of invasive pneumococcal disease

Effect of nationwide vaccination of 3-month-old infants in The Netherlands with conjugate Haemophilus influenzae type b vaccine: high efficacy and lack of herd immunity

Epidemiology of invasive meningococcal disease in the Netherlands

Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands

Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study

Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands

The National Immunisation Programme in the Netherlands: surveillance and developments in 2019-2020: Rijksinstituut voor Volksgezondheid en Milieu RIVM

A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination

A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker)

Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data

Short term impact of the COVID-19 pandemic on incidence of vaccine preventable diseases and participation in routine infant vaccinations in the Netherlands in the period

Invasive Meningococcal Disease, 2011-2020, and Impact of the COVID-19 Pandemic

Antigen-antibody reactions in gels

Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study

Invasive pneumococcal disease: Clinical outcomes and patient characteristics 2-6 years after introduction of 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period, the Netherlands

Rapid and Easy In Silico Serotyping of Escherichia coli Isolates by Use of Whole-Genome Sequencing Data

Serotypes, genotypes, and antibiotic susceptibility profiles of group B streptococci causing neonatal sepsis and meningitis before and after introduction of antibiotic prophylaxis

Increase in invasive disease caused by Haemophilus influenzae b, the Netherlands

The drop in reported invasive pneumococcal disease among adults during the first COVID-19 wave in the Netherlands explained

Serotype transmission dynamics and reduced incidence of invasive pneumococcal disease caused by different serotypes after implementation of non-pharmaceutical interventions during COVID-19 pandemic

Characteristics of Invasive Pneumococcal Disease Caused by Emerging Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in England: A Prospective Observational Cohort Study

The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: A systematic review and meta-analysis

Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries

Making sense of differences in pneumococcal serotype replacement

Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project

Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert review of vaccines

Re-emergence of invasive pneumococcal disease (IPD) and increase of serotype 23B after easing of COVID-19 measures

Re-emergence of Invasive Pneumococcal Disease in Germany during the Spring and Summer of 2021

Decline in pneumococcal disease in young children during the COVID-19 pandemic associated with suppression of seasonal respiratory viruses, despite persistent pneumococcal carriage: A prospective cohort study

Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap?